Aurobindo Pharma gains on USFDA nod for diabetes drug

Aurobindo Pharma gained on Friday after it has received tentative approval from the US Food & Drug Administration (USFDA) for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg. The product will be eligible for final approval upon the expiration of 180-day generic drug exclusivity.Shares ofthe companyare trading at Rs 143.95, up Rs 3.15, or 2.24% at the Bombay Stock Exchange (BSE) on Friday at 9:42 a.m.The scrip has touched an intra-day high of Rs 144.75 and low of Rs 141. The total volume of shares traded at the BSE is 106,885.In the earlier session, the shares climbed 0.28%, or Rs 0.40, at Rs 140.80. Currently, the stock is trading all time 52-week high, which is above 79.15% over the 52-week low of Rs 80.35.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 130.30 10.50 8.06 1 Month 112.20 28.60 25.49 3 Months 109.95 30.85 28.06 6 Months 118.90 21.90 18.42 1 Year 128.85 11.95 9.27 Note: Based on previous day closing price.